{"id":"ziprasidone-or-olanzapine","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Weight gain"},{"rate":"15-25","effect":"Sedation"},{"rate":"15-25","effect":"Metabolic syndrome (hyperglycemia, dyslipidemia)"},{"rate":"5-15","effect":"Akathisia"},{"rate":"5-10","effect":"Orthostatic hypotension"},{"rate":"1-5","effect":"QT prolongation (ziprasidone)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ziprasidone and olanzapine work by antagonizing dopamine D2 receptors in the mesolimbic and mesocortical pathways, which reduces positive symptoms of psychosis, while also blocking serotonin 5-HT2A receptors, which may enhance antipsychotic efficacy and reduce extrapyramidal side effects. Both agents are considered atypical antipsychotics due to their combined dopaminergic and serotonergic activity, distinguishing them from first-generation antipsychotics.","oneSentence":"Both ziprasidone and olanzapine are atypical antipsychotics that block dopamine D2 and serotonin 5-HT2A receptors to reduce psychotic symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:43.877Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar disorder (acute mania and maintenance)"},{"name":"Agitation associated with schizophrenia or bipolar disorder"}]},"trialDetails":[{"nctId":"NCT06049953","phase":"","title":"Maternal And Infant Antipsychotic Study","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-09-29","conditions":"Antipsychotics, Pregnancy","enrollment":200},{"nctId":"NCT04002700","phase":"","title":"A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-05-06","conditions":"Stroke","enrollment":1234412},{"nctId":"NCT02237417","phase":"PHASE4","title":"Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-01","conditions":"Schizophrenia","enrollment":47},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT06482554","phase":"PHASE3","title":"Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.","status":"RECRUITING","sponsor":"Louisiana State University Health Sciences Center Shreveport","startDate":"2024-06","conditions":"Apathy, Schizophrenia, Schizophrenia; Psychosis","enrollment":80},{"nctId":"NCT06040944","phase":"","title":"Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2022-09-01","conditions":"Schizophrenia Spectrum and Other Psychotic Disorders, Periodontal Diseases","enrollment":64},{"nctId":"NCT00448630","phase":"","title":"An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-10-23","conditions":"Schizophrenia, Metabolic Syndrome X","enrollment":328},{"nctId":"NCT03565068","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-20","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT00159770","phase":"PHASE3","title":"Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2001-11","conditions":"Schizophrenia, Schizoaffective Disorder, Psychotic Disorders","enrollment":290},{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":"Schizophrenia","enrollment":174},{"nctId":"NCT00338949","phase":"PHASE4","title":"Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes","status":"COMPLETED","sponsor":"Veterans Medical Research Foundation","startDate":"2006-06","conditions":"Schizophrenia, Metabolic Syndrome X, Insulin Resistance","enrollment":77},{"nctId":"NCT02181803","phase":"PHASE1","title":"MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-05","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT03007303","phase":"","title":"The Relevance Between the microRNA-30e in Plasma and the Prognosis of Schizophrenia Patients","status":"UNKNOWN","sponsor":"Dalian Seventh People's Hospital","startDate":"2016-06","conditions":"Schizophrenia, Micrognathia","enrollment":30},{"nctId":"NCT02600741","phase":"","title":"Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-24","conditions":"Schizophrenia","enrollment":296},{"nctId":"NCT01231074","phase":"PHASE1","title":"Reducing Antipsychotic-Induced Weight Gain in Children With Metformin","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2010-02","conditions":"Obesity, Weight Gain, Psychotropic Induced Weight Gain","enrollment":96},{"nctId":"NCT02307396","phase":"PHASE4","title":"Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-02-01","conditions":"Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders","enrollment":21},{"nctId":"NCT02529163","phase":"NA","title":"Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms","status":"UNKNOWN","sponsor":"Centre for Addiction and Mental Health","startDate":"2015-08","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":24},{"nctId":"NCT00509067","phase":"PHASE2","title":"Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2007-11","conditions":"Schizophrenia","enrollment":43},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT00806234","phase":"PHASE4","title":"Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-01","conditions":"Psychotic Disorders","enrollment":127},{"nctId":"NCT00351000","phase":"PHASE4","title":"Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus","status":"COMPLETED","sponsor":"North Suffolk Mental Health Association","startDate":"2005-01","conditions":"Schizophrenia","enrollment":24},{"nctId":"NCT02964923","phase":"","title":"Genes Polymorphisms and Metabolic Effects of the Second Generation Antipsychotic Drugs in Patients With Schizophrenia","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2016-04","conditions":"Schizophrenia","enrollment":300},{"nctId":"NCT00044655","phase":"PHASE4","title":"Switching Medication to Treat Schizophrenia","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2001-07","conditions":"Schizophrenia","enrollment":219},{"nctId":"NCT00177164","phase":"PHASE3","title":"Risperdal Consta for Bipolar Disorder","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2003-11","conditions":"Bipolar I Disorder","enrollment":50},{"nctId":"NCT02582736","phase":"","title":"Antipsychotics and Risk of Hyperglycemic Emergencies","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2012-04","conditions":"Psychotic Disorders, Schizophrenia, Schizoaffective Disorder","enrollment":725489},{"nctId":"NCT00225498","phase":"NA","title":"Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2002-06","conditions":"Schizophrenia","enrollment":35},{"nctId":"NCT01893229","phase":"PHASE4","title":"Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania","status":"UNKNOWN","sponsor":"Guiyun Xu","startDate":"2013-09","conditions":"Bipolar Disorder","enrollment":120},{"nctId":"NCT00488891","phase":"","title":"The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With Schizophrenia","status":"TERMINATED","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2007-04","conditions":"Schizophrenia","enrollment":43},{"nctId":"NCT00932529","phase":"PHASE4","title":"Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting","status":"COMPLETED","sponsor":"University of Bergen","startDate":"2003-02","conditions":"Psychotic Disorders","enrollment":226},{"nctId":"NCT01016145","phase":"PHASE4","title":"Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2009-04","conditions":"Schizophrenia or Schizoaffective Disorder","enrollment":126},{"nctId":"NCT00148564","phase":"PHASE4","title":"Energy Homeostasis Under Treatment With Atypical Antipsychotics","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2004-03","conditions":"Schizophrenia","enrollment":40},{"nctId":"NCT00347425","phase":"PHASE3","title":"Switch Study of Existing Atypical Antipsychotics to Bifeprunox","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2006-12","conditions":"Schizophrenia and Schizoaffective Disorder","enrollment":286},{"nctId":"NCT00297960","phase":"PHASE4","title":"Influence of Treatment With Olanzapine or Ziprasidone on Transcapillary Glucose Transport in Human Skeletal Muscle","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2005-04","conditions":"Healthy Male Volunteers","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11848,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ziprasidone or olanzapine","genericName":"ziprasidone or olanzapine","companyName":"Medical University of Vienna","companyId":"medical-university-of-vienna","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Both ziprasidone and olanzapine are atypical antipsychotics that block dopamine D2 and serotonin 5-HT2A receptors to reduce psychotic symptoms. Used for Schizophrenia, Bipolar disorder (acute mania and maintenance), Agitation associated with schizophrenia or bipolar disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}